Holen Sie sich die Stockscreener-App
62.32
1.37%
0.84
Handel nachbörslich:
62.32
Schlusskurs vom Vortag:
$61.48
Offen:
$61.55
24-Stunden-Volumen:
1.27M
Relative Volume:
0.53
Marktkapitalisierung:
$14.14B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$789.50M
KGV:
18.71
EPS:
3.33
Netto-Cashflow:
$1.15B
1W Leistung:
+2.15%
1M Leistung:
-1.41%
6M Leistung:
-22.89%
1J Leistung:
-19.43%
1-Tages-Spanne:
$61.41
$62.56
1-Wochen-Bereich:
$60.36
$62.56
52-Wochen-Spanne:
$60.34
$84.67
Hologic Inc Stock (HOLX) Company Profile
Firmenname
Hologic Inc
Sektor
Telefon
(508) 263-2900
Adresse
250 CAMPUS DRIVE, MARLBOROUGH, MA
Vergleichen Sie HOLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
62.32 | 14.14B | 4.03B | 789.50M | 1.15B | 3.33 |
|
ISRG
Intuitive Surgical Inc
|
507.90 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.71 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
96.80 | 47.88B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
222.62 | 32.70B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
33.70 | 17.29B | 17.28B | 108.00M | 391.00M | 0.20 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-03 | Herabstufung | Argus | Buy → Hold |
| 2025-02-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | Herabstufung | Needham | Buy → Hold |
| 2024-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-12-10 | Bestätigt | Needham | Buy |
| 2024-10-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-27 | Eingeleitet | Stephens | Overweight |
| 2024-04-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-07-14 | Hochstufung | Needham | Hold → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-07-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-07-20 | Eingeleitet | UBS | Neutral |
| 2022-07-18 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-11-20 | Herabstufung | Needham | Buy → Hold |
| 2020-11-05 | Bestätigt | Needham | Buy |
| 2020-06-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-06-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | Bestätigt | Needham | Buy |
| 2020-04-30 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-01-31 | Bestätigt | Needham | Buy |
| 2019-01-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-09-13 | Herabstufung | BofA/Merrill | Buy → Neutral |
Alle ansehen
Hologic Inc Aktie (HOLX) Neueste Nachrichten
Photodynamic Therapy Market 2025: Sustainable Growth, Key - openPR
Hologic Stock: Is HOLX Underperforming the Healthcare Sector? - MSN
Hologic Stock: Is HOLX Underperforming The Healthcare Sector? - Barchart
Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News
Analysis of China's $1.13 Billion Biopsy Devices Market, - GlobeNewswire
Analysis of China's $1.13 Billion Biopsy Devices Market, 2025-2033: Cardinal Health, Hologic, and Danaher Corporation Lead the Competition - Yahoo Finance
Hologic (HOLX) Advances But Underperforms Market: Key Facts - Yahoo Finance
Investing in Hologic (NASDAQ:HOLX) five years ago would have delivered you a 76% gain - Yahoo Finance
Molecular Diagnostics Market Is Booming Worldwide 2025-2032 | - openPR
Biopsy Devices Market Generated Opportunities, Future Scope - openPR
Breast Biopsy Devices Market Is Booming Worldwide 2025-2032 | - openPR
New Product Launches to Support HOLX Stock Amid Macro Issues - MSN
Liposuction Surgery Devices Market Growth Report and - GlobeNewswire
Liposuction Surgery Devices Market Growth Report and Company Analysis 2025-2033 Featuring SOLTA MEDICAL, InMode, Genesis Biosystems, Hologic, Apyx Medical, Cynosure, YOLO Medical, and Sciton - Yahoo Finance
Mammography Market is projected to witness lucrative growth - openPR
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip? - Yahoo Finance
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know - Yahoo Finance
Redburn Atlantic Adjusts Hologic Price Target to $72 From $82, Keeps Neutral Rating -March 18, 2025 at 12:32 pm EDT - Marketscreener.com
Gynecological Devices Market 2025-2032 is Thriving Worldwide - openPR
Hologic (HOLX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
In Vitro Diagnostics Market reached US$ 84.90 billion in 2024 - openPR
Ultrasound Market Industry Report 2025, with Focus on Key Players CHISON Medical Technologies, Clarius, Draminski, Esaote, GE HealthCare, Hologic, Promed Technology, SIUI, SonoScape & more - Yahoo Finance
Transplantation Market Growth | Trends, Opportunities & Global Forecast 2024-2031 | Hologic, Inc, QIAGEN, XVIVO. - openPR
Fluoroscopy and C-Arm Market Growth in Future Scope 2025-2032 | - openPR
Hologic stock hits 52-week low at $61.67 amid market shifts - Investing.com Australia
Hologic stock hits 52-week low at $61.67 amid market shifts By Investing.com - Investing.com South Africa
Fluoroscopy Devices Market Set to Expand Due to Rising Demand - openPR
Clinical Diagnostic Market Set for Strong Growth | Advanced - openPR
Is Hologic, Inc. (NASDAQ:HOLX) Potentially Undervalued? - Simply Wall St
Breast Cancer Screening Market to Hit $11.7 Billion by 2033Key - openPR
Molecular Diagnostics Market Business Opportunities - openPR
Cancer Diagnostics Market Top PlayersGE Healthcare, Abbott - openPR
BioZorb Lawuit LawyerBreast Biopsy Marker RecallMarch 2025 Update - Levin Papantonio
Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Mutual of America Capital Management LLC - Defense World
Why Is Hologic (HOLX) Down 4.5% Since Last Earnings Report? - Yahoo Finance
Lumos expands development deal with Hologic for premature birth test - MSN
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock - Yahoo Finance Australia
Cosmetic Surgery Market Forecast Report and Company - GlobeNewswire
Cosmetic Surgery Market Forecast Report and Company Analysis 2025-2033 Featuring AbbVie, Cutera, Sientra, Bausch Health, Johnson & Johnson, Apyx Medical, Hologic, Merz Pharma, Galderma, Cynosure - Yahoo Finance
Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Mammography Machine Market Expands: $2.6 Bn in 2024 to $4.1 Bn - openPR
X-ray Machine Manufacturing Market to Witness Remarkable - openPR
Digital X-ray Devices Market to Witness Remarkable Growth with Hologic, Inc., Hitachi, Ltd., Siemens Healthineers - openPR
Hologic (NASDAQ:HOLX) Price Target Cut to $70.00 by Analysts at Citigroup - Defense World
Fluoroscopy Devices Market Projected To Witness Massive - openPR
Hologic (NASDAQ:HOLX) Sets New 1-Year Low After Analyst Downgrade - Defense World
Hologic stock touches 52-week low at $62.67 amid market shifts - Investing.com Canada
Breast Cancer Brachytherapy Market Future Business - openPR
11 Analysts Have This To Say About Hologic - Benzinga
Hologic cut to Hold at Argus amid slower mammography equipment sales - Yahoo Finance
Lumos expands deal for premmie birth test - NT News
Finanzdaten der Hologic Inc-Aktie (HOLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):